Background. Nephrotic syndrome (NS), a chronic kidney disease, is characterized by significant loss of protein in the urine causing hypoalbuminemia and edema. In general, $15% of childhood-onset cases do not respond to steroid therapy and are classified as steroid-resistant NS (SRNS). In $30% of cases with SRNS, a causative mutation can be detected in one of 44 monogenic SRNS genes. The gene LAMA5 encodes laminin-a5, an essential component of the glomerular basement membrane.
81. Kambham N, Tanji N, Seigle RL et al. Congenital focal segmental glomerulosclerosis associated with beta4 integrin mutation and epidermolysis bullosa. was strongly suspected based on pedigree information, we identified homozygous variants of unknown significance (VUS) in the gene LAMA5. While all affected individuals had nonsyndromic NS with an early onset of disease, their clinical outcome and response to immunosuppressive therapy differed notably. Conclusion. We here identify recessive VUS in the gene LAMA5 in patients with partially treatment-responsive NS. More data will be needed to determine the impact of these VUS in disease management. However, familial occurrence of disease, data from genetic mapping and a mouse model that recapitulates the NS phenotypes suggest that these genetic variants may be inherited factors that contribute to the development of NS in pediatric patients.
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Nephrotic syndrome (NS), a chronic kidney disease, is characterized by proteinuria (>40 mg/m 2 /h) that causes hypoalbuminemia, edema and hyperlipidemia. While most affected children and young adults show a clinical response to steroid therapy, $10-15% of cases exhibit steroid-resistant NS (SRNS; defined as persistent proteinuria after 6 weeks of oral steroid treatment) [1, 2] . Patients with steroid-sensitive NS (SSNS) can have a single episode of NS, responding promptly to therapy, or show a complicated clinical course with frequent relapses of NS after termination of steroid therapy. Some patients who are resistant to steroid therapy may still respond to a more intensified drug regimen with different immunosuppressive drugs, whereas others are completely resistant to therapy [3] . This observation suggests that in some cases SSNS and SRNS can represent a continuum of the same disease rather than being two distinct disease entities. Early response to therapy is a strong predictor of longterm renal outcome [4] , and patients with SRNS progress almost inevitably to end-stage renal disease (ESRD) [2] . In patients with SRNS, the most frequently observed histological diagnosis on renal biopsy is focal segmental glomerulosclerosis (FSGS) [5] . Patients displaying minimal change nephropathy (MCN) on renal biopsy when first diagnosed tend to have better outcomes [4] . However, frequently MCN evolves into FSGS over time [5] . Despite intensive research, no effective treatment for FSGS/SRNS exists and FSGS constitutes the third most frequent cause of ESRD in childhood and adolescence [6] .
The discovery of monogenic causes of SRNS has identified glomerular podocytes as the primary site of damage in this disease, because many genes that, if mutated, cause SRNS are predominantly expressed in this cell type [7, 8] . Mutations in four genes, namely NPHS1, NPHS2, LAMB2 and WT1, are most frequently observed, and together explain up to 66% of cases with an onset of SRNS within the first year of life [9] . Advances in next-generation sequencing have facilitated the identification of more than 44 genes that cause SRNS if mutated [10, 11] . It was recently shown in a worldwide study in 1873 families that in 29.5% of cases with an onset of SRNS before age 25 years, a causative single-gene mutation could be identified [12] . This finding was confirmed in two additional studies that demonstrated monogenic disease causation in 26.2% and 32.3% of patients with SRNS, respectively [13, 14] .
The glomerular filter, which is functionally impaired in NS, consists of podocytes, fenestrated endothelial cells, mesangial cells and the glomerular basement membrane (GBM). One essential component of the GBM is laminin, which forms obligate heterotrimers composed of a, b and c chains [15] . Laminins and integrin receptors are important for cross talk between podocytes and the GBM [16] . Laminin-a5, the predominant a-chain in the mature GBM [17] , is encoded by the gene LAMA5. Knockout of Lama5 in mice causes embryonic lethality and severe defects of glomerular development [18] . In contrast, mice with a hypomorphic Lama5 allele in the homozygous state demonstrated proteinuria, cystic kidney disease and death from progressive renal failure at 3-4 weeks of age [19] . Interestingly, Lama5 mutations in mice have a strictly recessive mode of inheritance and heterozygous mice were indistinguishable from wild-type litter mates [18] . Two previous publications suggested an association between heterozygous mutations of LAMA5 and adult-onset FSGS [20, 21] .
We here performed whole exome sequencing (WES) in 335 individuals of 300 families with NS. After excluding likely disease-causing mutations in known monogenic causes of SRNS, we used homozygosity mapping in consanguineous families and identified recessive mutations in the gene LAMA5 in three unrelated families with childhood-onset NS that responded to immunosuppressive therapy.
M A T E R I A L S A N D M E T H O D S

Study participants
Following informed consent, we obtained pedigree information, clinical data and blood samples from individuals with proteinuria or NS (onset <25 years of age). Study approval was obtained from the institutional review boards of the University of Michigan and Boston Children's Hospital. Patients were enrolled between 1998 and 2016. We performed WES in 335 individuals from 300 families. Patients were recruited in collaborating centers worldwide and were ethnically diverse. Individuals of consanguineous kindred were preferentially sent for WES.
Treatment response to immunosuppressive therapy in NS was defined as follows: complete response-remission of proteinuria, with a urine protein:creatinine ratio of <0.2 mg/mg, normalization of albumin; partial response-a decrease in proteinuria by 50%; resistance-persistent, fixed proteinuria.
In cases with complete response, the absence of proteinuria was confirmed in laboratory values of negative proteinuria either in a 24-h urine specimen or in the first morning urine specimen.
A total of 258 patients with renal ciliopathies based on increased echogenicity and/or cysts on renal ultrasound who did not have proteinuria were used as a control cohort. Informed consent, sample processing and WES evaluation were performed as for NS samples.
WES
Genomic material deoxyribonucleic acid (DNA) for WES was extracted from saliva or blood lymphocytes. Following library preparation and exome capture using the Agilent SureSelect human exome capture arrays (Life Technologies, Carlsbad, CA, USA), next-generation sequencing was performed on a HighSeq platform (Illumina, San Diego, CA, USA). Sequence reads were aligned to the human reference genome (National Center for Biotechnology Information build 37/hg19) using CLC Genomics Workbench (version 6.5.2) (CLC bio, Aarhus, Denmark). Subsequent bioinformatics analysis excluded all variants with a minor allele frequency >1% in the Short Genetic Variations database (dbSNP, version 142) or in the 1000 Genomes Project database (1094 subjects of various ethnicities; May 2011 data release). Noncoding variants outside canonical splice regions as well as synonymous variants were excluded, and variants were annotated using the Exome Aggregation Consortium (ExAC) database. Variants that were reported more than 10 times in the homozygous state in the ExAC database were excluded as likely nonpathogenic polymorphisms. Remaining variants were ranked based on established criteria [10, 11, 22] and were evaluated for likely pathogenicity under consideration of phenotypic as well as pedigree information.
Homozygosity mapping
Homozygosity mapping was calculated based on WES data. In brief, aligned Binary Alignment Map files were processed using Picard and SAMtools4 as described by other groups [23] . Single-nucleotide variant calling was performed using Genome Analysis Tool Kit [24] . The resulting variant call format files were used to generate homozygosity mapping data and visual outputs using the program HomozygosityMapper [25] .
Screening for mutations in known monogenic causes of SRNS
We concatenated the genomic loci of 34 genes that are known to cause SRNS if mutated (Supplementary data, Table S1 ). Aligned reads from WES data for all 335 individuals were first filtered using this file and evaluated for potentially diseasecausing variants in these known monogenic genes of SRNS. Further analysis seeking potential novel candidate genes was only performed if no likely pathogenic mutation was identified.
Variant filtering to identify novel monogenic causes of NS
We used homozygosity mapping data in consanguineous families (>100 Mb of cumulative homozygosity according to mapping) to identify genomic candidate loci for the underlying recessive mutation. Within these areas we restricted our analysis to homozygous mutations. Remaining calls were ranked for their predicted pathogenicity based on the following criteria [10, 11, 22] : (i) protein truncating or obligatory splice site mutation versus missense mutation or in-frame deletion/insertion, (ii) evolutionary conservation, (iii) minor allele frequency in control databases [ All websites were last accessed on 2 February 2018.
R E S U L T S
Recessive variants of LAMA5 in patients with NS
We performed WES in 335 individuals of 300 families with NS. As a first step, we excluded likely disease-causing mutations in 34 genes that are known to cause monogenic NS if mutated (Supplementary data, Table S1 ). We subsequently used homozygosity mapping in consanguineous families to identify candidate loci for the underlying recessive mutation. In three unrelated families with NS that shared a homozygous peak region on chromosome 20q13 (Figure 1) , we identified three different homozygous variants of unknown significance (VUS) in the gene LAMA5 (NM_005560.4) encoding laminin-a5. In family A4389 from Turkey we detected the variant c.2239 C >T, p.Arg747Trp, conserved to Drosophila melanogaster; in family B150 from Egypt we detected the variant c.3002 A>G, p.Glu1001Gly, conserved to Ciona intestinalis; and in family B1284 from Saudi Arabia we identified the variant c.8842 G>A, p.Gly2948Ser, conserved to D. melanogaster (Table 1, Figure 2) .
Each family had two affected children with NS, strongly suggesting an inherited cause of disease. The parents, who were heterozygous carriers of the VUS, were phenotypically healthy and did not have proteinuria. In family B1284, a DNA sample for the younger sibling was not available. In the other two families (A4389 and B150) we demonstrated the presence of the homozygous VUS in both affected children. Segregation analysis in families B150 and B1284 showed that, as expected in a recessive mode of inheritance, the parents were healthy heterozygous carriers of the VUS ( Figure 2D ). All three VUS were missense alleles affecting amino acid residues of strong LAMA5 variants in pediatric NS evolutionary conservation among orthologue proteins of laminin-a5 ( Figure 2C , Table 1 ). Bioinformatics scoring programs (SIFT, PolyPhen-2 and MutationTaster) predicted the impact of the identified variants as likely pathogenic (Table 1) . Furthermore, none of the three variants has been reported in the homozygous state in databases of healthy control populations (EVS and gnomAD [27] ) ( Table 1 ). The protein laminin-a5 carries an N-terminal LN (laminin N-terminal) domain, followed by multiple epidermal growth factor (EGF) domains and 5 C-terminal laminin G-like (LamG) domains. Interestingly, two of the variants affected amino acid residues that are located within one of the functional domains of the protein, namely the ninth EGF-like domain (p.Arg747Trp, A4389) and the second laminin G-like domain (p.Gly2948Ser, B1284) ( Figure 2B , Table 1 ).
Because individuals of Middle Eastern descent are poorly represented in publicly available control databases, we used 258 individuals with renal ciliopathies, a different entity of inherited kidney disease in which proteinuria is characteristically absent, as a control cohort. However, we did not identify recessive mutations in the LAMA5 gene in these individuals.
Treatment response and renal outcome differ in three families with VUS in LAMA5 and NS
All five patients in whom we detected homozygous VUS in LAMA5 shared the phenotype of NS with onset before 4 years of age. Extrarenal manifestations or syndromic features were not present in any of the affected children. However, the five children differed notably in their response to immunosuppressive treatment, their clinical presentation and regarding progression to ESRD. 3In family A4389, the two children presented with NS at ages 22 months and 3 years, respectively. Both siblings responded promptly to steroids but had frequent relapses within the first year of diagnosis. Subsequently, stable remission was achieved and they have been maintained off steroids without further relapse for an interval of 3 years (at the time of this publication). The younger sibling received cyclophosphamide due to steroid dependency. No A, African (allele frequencies, gnomAD); DC, predicted to be disease-causing (SIFT); del, predicted to be deleterious (MutationTaster); E, European (allele frequencies, gnomAD); EA, East Asian (allele frequencies, gnomAD); het, heterozygous; hom, homozygous; IS, immunosuppressive therapy; m, maternal; mo, months; n/a; not applicable; ND, no data; n.p., no biopsy performed; m, maternal; MMF, mycophenolate mofetil; p, paternal; PPH2 score humvar PolyPhen2 prediction score; SA, South Asian (allele frequencies, gnomAD); SDNS, steroid-dependent nephrotic syndrome; Tac, tacrolimus; tol, tolerated; yrs, years.
further immunosuppressive therapy was required and both siblings showed normal renal function and persistent remission of NS at ages 11 and 9 years, respectively ( Table 1) . The two siblings of family B150 had their first episode of NS at ages 1.5 and 4 years, respectively. Both siblings developed SRNS. However, while the older sibling (B150-21) initially responded to steroids and only later developed SRNS, the younger sibling (B150-22) had SRNS at her initial presentation. The renal histology in both siblings demonstrated FSGS and the younger sister progressed to ESRD by the age of 6 years. Unfortunately, this patient died prior to renal transplantation so data on disease recurrence after transplantation are not available.
Individual B1284-21 first presented with NS at 4 years of age. He initially responded to steroid therapy but had frequent relapses and ultimately developed steroid-dependent NS, requiring additional immunosuppressive agents to achieve remission. He has a younger brother with a similar clinical presentation. However, his genotype is not known because a DNA sample for genetic analysis could not be obtained.
D I S C U S S I O N
We here identify recessive VUS in the gene LAMA5 in three unrelated families with two children each with childhood-onset NS. The familial occurrence and presence of homozygosity in all three families strongly suggested a recessive cause of disease. We excluded mutations in 34 genes that are known to cause NS, if mutated. By homozygosity mapping, we identified the LAMA5 locus as a candidate region common to all three families. We then used WES and identified recessive VUS in the LAMA5 gene in all three families. However, because experimental evidence is lacking, the impact of these genetic variants on protein function and disease pathogenesis cannot be judged with certainty. Therefore, more data are needed to evaluate the functional relevance of these VUS in NS and to determine their potential impact on prognosis and disease management.
While~80% of pediatric patients with NS promptly respond to therapy with steroids, inherited forms of the disease typically present with the phenotype of SRNS. We and others have previously shown that, depending on age of onset, consanguinity and familial occurrence of disease, in~30% of SRNS cases a causative single-gene mutation can be identified [12] [13] [14] . Having a conclusive, monogenic diagnosis provides affected patients and their families with an unequivocal diagnosis, can help guide therapy and predicts a lower risk for disease recurrence after renal transplantation [5] . Therefore, genetic testing should be implemented as the standard of care in all patients with SRNS [10] . However, considering the growing number of known monogenic causes of SRNS and better availability of genetic testing, it becomes increasing important to determine standardized criteria that help distinguish polymorphisms from true pathogenic variants [28] . This is particularly important if functional data for the identified variants are lacking and if ethnically matched control populations are unrepresented in available large datasets [27] .
Familial cases of SSNS have been described [29] and genetic causation may not be limited to patients with NS that is strictly resistant to drug treatment. This was first observed for the gene EMP2, which, if mutated, caused a steroid-sensitive form of NS in some patients [30] . Subsequently, recessive mutations of TNS2, DLC1, CDK20, ITSN1 and ITSN2 were found to cause partially treatment-sensitive NS [31] . Our findings suggest that VUS of LAMA5 may contribute to the development of a form of NS that in some patients responds to drug treatment. Traditionally, SSNS and SRNS are regarded as two distinct disease entities, and it has been proposed that the pathogenesis of SSNS is likely immune mediated [32] . Interestingly, the three families with VUS in LAMA5 differed significantly in their response to drug therapy, ranging from SSNS to SRNS, including one family with an intermediate phenotype (B1284, Table 1 ). The observation that the same molecular defect, an alteration of the laminin-a5 protein, can act as a contributing factor in the pathogenesis of both phenotypes (SSNS and SRNS) may suggest that steroid resistance and steroid sensitivity in NS occupy a phenotypic spectrum.
Despite their long-term therapeutic use, the exact mode of action of steroids is unknown. Growing evidence suggests that in addition to their immunoregulatory function, immunosuppressive drugs also act directly on podocytes [33, 34] . Via direct binding to the mineralocorticoid receptor, which has been shown to be expressed in podocytes, steroid therapy induced changes in the podocyte transcriptome [35] . In addition, it has been shown that cyclosporine A (CsA) acts directly on the podocyte actin cytoskeleton, thereby influencing actin dynamics [36] . While inherited forms of NS are characteristically regarded as nonresponsive to immunosuppressive therapy, there are also some reports demonstrating that CsA can be effective in patients with Alport syndrome [37] . Alport syndrome is a form of inherited glomerulopathy caused by mutations in genes that encode collagens of the GBM. Based on these observations, one could speculate that steroids act directly or indirectly on components of the GBM by changing the gene expression profile of podocytes.
Heterozygous mutations in the gene LAMA5 have been previously reported by two other groups as being associated with adult-onset FSGS in an autosomal dominant manner [20, 21] . However, the pathogenicity of the heterozygous mutations described in LAMA5 remains controversial [21] . In addition, a genetic mouse model of Lama5, in which heterozygous mice are phenotypically indistinguishable from wild-type littermates, demonstrates a strictly recessive mode of inheritance [18] . In accordance with these findings, heterozygous parents in our study did not manifest with NS. However, it is possible that, as described for other genes, such as COL4A3 and COL4A4 [38] , heterozygous carriers may manifest with adult-onset disease of variable penetrance, whereas recessive mutations cause a fully penetrant, early-onset disease manifestation. Further studies will be required to determine the pathogenicity of heterozygous mutations of LAMA5.
The mouse orthologue Lama5 encodes Laminin-a5, an essential component of basement membranes. A complete genetic knockout of Lama5 in mice caused various developmental defects and was embryonic lethal at e14-e17 [39] . A targeted deletion of Lama5 in the kidney resulted in severely disrupted glomerulogenesis, defects in branching of the ureteric bud and sporadic renal agenesis [18] . Both findings suggest an important function of Laminin-a5 during renal development and glomerular maturation. Interestingly, a hypomorphic Lama5 allele (Lama5 neo ) allowed normal formation of glomerular architecture but caused delayed onset of proteinuria with thickening of the GBM and secondary glomerulosclerosis [15, 19] . This finding is consistent with the phenotype that we observed in three families with recessive, hypomorphic VUS of LAMA5. Furthermore, Lama5 hypomorphic mice developed polycystic kidney disease [19] . In contrast, the renal ultrasound in all five patients with VUS in LAMA5 was unremarkable. In particular, no cystic lesions were detected and there were no radiological signs of congenital malformations of the kidney or urinary tract.
In summary, we here identify recessive VUS in the LAMA5 gene as genetic variants that may contribute to the development LAMA5 variants in pediatric NS of NS in pediatric patients. Interestingly, some of the described patients responded partially to steroids or other immunosuppressive drug regimens, whereas others were resistant to therapy. Additional data are required to determine the impact of genetic variants in the LAMA5 gene on the pathogenesis, prognosis and potentially on disease management in pediatric patients with NS.
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